THOMPSON ELIZABETH H.Z. (EVP, Head of Research & Dev) sold 46.6% of their position (16.56K shares) of ACADIA PHARMACEUTICALS INC on the open market
Open‑market sale worth $432.7K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 7/31/2026ACC: 0001861477-26-000005
Officer· EVP, Head of Research & Dev
Since Mar 2026
-16.56K
Net shares
Net seller
$432.7K
Total sold
2
Open market trades
0B · 2S
4
Total transactions
32.27K acquired · 48.83K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
+32.27K
Price / share
—
Trade value
—
% of position
983.9%
7/29/2026
3.28K→35.55K
Common Stock
Direct
Shares
−16.51K
Price / share
$26.13
Trade value
$431.35K
% of position
46.4%
7/30/2026
35.55K→19.04K
Common Stock
Direct
Shares
−50.00
Price / share
$26.17
Trade value
$1.31K
% of position
0.3%
7/30/2026
19.04K→18.99K
Total
Net shares
+15.71K
Net value
-$432.66K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/29/2026 | M · Option Exercise | +32.27K | — | — | 983.9% | 3.28K | 35.55K |
| Common Stock Direct | 7/30/2026 | S · Sale | −16.51K | $26.13 | $431.35K | 46.4% | 35.55K | 19.04K |
| Common Stock Direct | 7/30/2026 | S · Sale | −50.00 | $26.17 | $1.31K | 0.3% | 19.04K | 18.99K |
| Total | +15.71K | -$432.66K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Stock
32.27K shares
Shares
−32.27K
Strike price
Held after
32.27K
Exercisable
—
7/29/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock32.27K shares | 7/29/2026 | M · Option Exercise | −32.27K | — | 32.27K |